Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28154838 | 0.87 | NPC1 (0.44) | NPC1HPGDRAB9ASMN1; SMN2ACHE | |
| SCHEMBL28183920 | 0.75 | NPC1 (0.55) | NPC1HPGDRAB9ASMN1; SMN2ACHE | |
| SCHEMBL5008184 | 0.75 | NPC1 (0.55) | NPC1HPGDRAB9ASMN1; SMN2ACHE | |
| SCHEMBL2013877 | 0.75 | NPC1 (0.55) | NPC1HPGDRAB9ASMN1; SMN2ACHE | |
| SCHEMBL904938 | 0.75 | NPC1 (0.55) | NPC1HPGDRAB9ASMN1; SMN2ACHE | |
| SCHEMBL28296344 | 0.75 | HPGD (0.50) | NPC1HPGDRAB9ASMN1; SMN2ACHE | |
| SCHEMBL28147613 | 0.75 | NPC1 (0.50) | NPC1HPGDRAB9ASMN1; SMN2ACHE | |
| SCHEMBL28228313 | 0.74 | RAB9A (0.46) | NPC1HPGDRAB9ASMN1; SMN2ACHE | |
| Hydrochloric Acid SCHEMBL5010650 | 0.73 | NPC1 (0.58) | NPC1HPGDRAB9ASMN1; SMN2ACHE | |
| SCHEMBL28154872 | 0.73 | ACHE (0.44) | NPC1HPGDRAB9ASMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115124530-B | Preparation method of evodiamine | 江西师范大学 | 2023-04-07 | — | — | CN | claimed |
| CN-115141199-B | Novel method for synthesizing rutaecarpine | 江西师范大学 | 2023-04-07 | — | — | CN | claimed |
| CN-115141199-A | Novel method for synthesizing rutaecarpine | 江西师范大学 | 2022-10-04 | — | — | CN | claimed |
| CN-115124530-A | Preparation method of evodiamine | 江西师范大学 | 2022-09-30 | — | — | CN | claimed |
| US-20060156485-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-20 | — | — | US | claimed |
| CN-115124530-B | Preparation method of evodiamine | 江西师范大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115141199-B | Novel method for synthesizing rutaecarpine | 江西师范大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115141199-A | Novel method for synthesizing rutaecarpine | 江西师范大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-115124530-A | Preparation method of evodiamine | 江西师范大学 | 2022-09-30 | — | — | CN | disclosed |
| EP-3444238-B1 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | SATO PHARMA (JP) | 2021-12-08 | — | — | EP | disclosed |
| EP-3444238-A2 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | Sato Pharmaceutical Co., Ltd. (JP) | 2019-02-20 | — | — | EP | disclosed |
| EP-2878594-B1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMA (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060156485-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-20 | — | — | US | disclosed |
| CN-1076445-A | The phenylquinazoline derivates that replaces | SANDOZ LTD (US) | 1993-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | NPC1 1762/4885HPGD 1054/4885RAB9A 1763/4885 |
| US-20060156485-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, TUBB6, DNMT1 | NPC1 4475/4885HPGD 158/4885RAB9A 3802/4885 |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | NPC1 2186/4885HPGD 573/4885RAB9A 3692/4885 |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | NPC1 630/4885HPGD 1043/4885RAB9A 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.